stoxline Quote Chart Rank Option Currency Glossary
  
aTyr Pharma, Inc. (ATYR)
4.195  0.405 (10.69%)    02-19 13:55
Open: 3.86
High: 4.285
Volume: 2,950,898
  
Pre. Close: 3.79
Low: 3.85
Market Cap: 352(M)
Technical analysis
2025-02-19 1:18:19 PM
Short term     
Mid term     
Targets 6-month :  5 1-year :  5.84
Resists First :  4.28 Second :  5
Pivot price 3.76
Supports First :  3.68 Second :  3.31
MAs MA(5) :  3.69 MA(20) :  3.71
MA(100) :  3.2 MA(250) :  2.35
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  52.9 D(3) :  41.3
RSI RSI(14): 60.6
52-week High :  4.28 Low :  1.41
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ATYR ] has closed below upper band by 4.9%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.83 - 3.85 3.85 - 3.88
Low: 3.46 - 3.49 3.49 - 3.52
Close: 3.74 - 3.79 3.79 - 3.84
Company Description

Headline News

Wed, 19 Feb 2025
aTyr Pharma Stock Soars to 52-Week High of $4.22 Amidst Strong Growth - Investing.com

Wed, 19 Feb 2025
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Wed, 19 Feb 2025
Atyr PHARMA (NASDAQ:ATYR) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat

Tue, 18 Feb 2025
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation - Nasdaq

Tue, 18 Feb 2025
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Tue, 18 Feb 2025
Leerink Partners Initiates Coverage on aTyr Pharma With Outperform Rating, $16 Price Target - Marketscreener.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 84 (M)
Held by Insiders 7.69e+007 (%)
Held by Institutions 2.1 (%)
Shares Short 3,650 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.734e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -28 %
Return on Assets (ttm) 958.7 %
Return on Equity (ttm) -39.3 %
Qtrly Rev. Growth 235000 %
Gross Profit (p.s.) 0
Sales Per Share -70.4
EBITDA (p.s.) -4.92432e+007
Qtrly Earnings Growth -1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -67 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 5.24
Stock Dividends
Dividend 0
Forward Dividend 3.82e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android